Monday, December 22, 2008

FDA Issues Complete Response Letter to Centocor for Ustekinumab BLA

Centocor, Inc., announced today that the U.S. FDA issued a Complete Response letter for its Biologics License Application (BLA) for ustekinumab.

The details can be read here.
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)